Because there are many possible explanations for such discrepancies, we decided to re-evaluate the role of PARP inhibition in the treatment of gliomas using multiple BTIC lines derived from newly diagnosed and recurrent GBMs and oligodendrogliomas and in orthotopic xenografts. Here, PARP1 is linked to central nervous system cancer.